مهمان عزیز شما حق دیدن لینک ها را ندارید برای استفاده از امکانات کامل انجمن عضو شوید

عضویت

Among patients who have complete pathologic complete response to neoadjuvant chemotherapy in combination with her 2 targeted agents like trastuzumab Herceptin or trastuzumab pertuzumab Perjeta, they have an excellent outcome with completing therapy with trastuzumab alone after definitive surgery and radiation alone, whereas patients who do not have a pathologic response will benefit from TDM 1 Kadcyla for an additional 14 treatments in addition to their definitive surgery and radiation as indicated